ATOSSA THERAPEUTICS, INC. Cash Flow Statement
ATOS|5 years of annual SEC 10-K data (FY2012-FY2016)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
ATOSSA THERAPEUTICS, INC. used $14M in operating cash flow in FY2016.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -15.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|
| Net Income | -$15.8M | -$14.7M | -$10.8M | -$122.9K | -$122.9K |
| Depreciation & Amortization | $272.6K | $480.3K | $472.9K | $130.6K | $15.6K |
| Operating Cash Flow | -$14.0M | -$10.6M | -$8.8M | -$3.9M | -$3.5M |